DE10143840A1 - New acylated hydroxamates useful for the treatment of e.g. wound healing - Google Patents
New acylated hydroxamates useful for the treatment of e.g. wound healingInfo
- Publication number
- DE10143840A1 DE10143840A1 DE10143840A DE10143840A DE10143840A1 DE 10143840 A1 DE10143840 A1 DE 10143840A1 DE 10143840 A DE10143840 A DE 10143840A DE 10143840 A DE10143840 A DE 10143840A DE 10143840 A1 DE10143840 A1 DE 10143840A1
- Authority
- DE
- Germany
- Prior art keywords
- branched
- unbranched
- chain
- compounds
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000029663 wound healing Effects 0.000 title claims description 5
- 150000001413 amino acids Chemical class 0.000 claims abstract description 24
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 22
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 22
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 21
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 17
- 102000004190 Enzymes Human genes 0.000 claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 claims abstract description 12
- 125000003118 aryl group Chemical group 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 5
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims abstract description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 37
- 101000870232 Tenebrio molitor Diuretic hormone 1 Proteins 0.000 claims description 20
- 150000001450 anions Chemical class 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000002346 iodo group Chemical group I* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960002591 hydroxyproline Drugs 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 108010016626 Dipeptides Proteins 0.000 abstract description 4
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 abstract description 4
- -1 carbocyclicoxy Chemical group 0.000 abstract description 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 3
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 abstract description 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 150000003568 thioethers Chemical class 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 description 14
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 12
- 102000003902 Cathepsin C Human genes 0.000 description 10
- 108090000267 Cathepsin C Proteins 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 235000019833 protease Nutrition 0.000 description 10
- 102000005927 Cysteine Proteases Human genes 0.000 description 7
- 108010005843 Cysteine Proteases Proteins 0.000 description 7
- 230000002427 irreversible effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000007801 affinity label Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000937 inactivator Effects 0.000 description 4
- 230000002132 lysosomal effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 3
- 102000018389 Exopeptidases Human genes 0.000 description 3
- 108010091443 Exopeptidases Proteins 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 108050004038 cystatin Proteins 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004963 pathophysiological condition Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- ZYJSTSMEUKNCEV-UHFFFAOYSA-N 3-diazo-1-diazonioprop-1-en-2-olate Chemical compound [N-]=[N+]=CC(=O)C=[N+]=[N-] ZYJSTSMEUKNCEV-UHFFFAOYSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000619 Cathepsin H Proteins 0.000 description 1
- 102000004175 Cathepsin H Human genes 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- 108700036514 EC 3.4.14.1 Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108010015596 cathepsin J Proteins 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 1
- 229920005591 polysilicon Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 108010056337 somatostatin-28 convertase Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft Verbindungen, die als spezifische Inhibitoren der Cysteinprotease Dipeptidyl Peptidase I (DP I) wirken. Diese Verbindungen werden durch die allgemeine Formel R-A-B-NH-O-C(O)R' repräsentiert, in der R eine verzweigte oder unverzweigte C1-9 Alkylkette, eine verzweigte oder unverzweigte C2-9 Alkenylkette, eine verzweigte oder unverzweigte C2-9 Alkinylkette, ein C3-9 Cycloalkyl, C4-9 Cycloalkenyl, C5-14 Aryl, alle vorstehenden Reste optional substituiert, oder H ist, A eine Aminosäure oder ein Mimetikum dieser Aminosäure ist, die in Peptidbindung mit B vorliegt, B eine Aminosäure oder ein Mimetikum dieser Aminosäure, außer Prolin und Hydroxyprolin, ist und R' eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9 Alkinylkette, ein C3-9 Cycloalkyl, C4-C9 Cycloalkenyl, C2-C9 Heterocycloalkyl, C3-C9 Heterocycloalkenyl, C5-14 Aryl, das im Ring bis zu 6 Heteroatome aufweisen kann, eine Aminosäure oder ein Mimetikum dieser Aminosäure, alle vorstehenden Reste optional substituiert, oder H ist. The present invention relates to compounds which act as specific inhibitors of the cysteine protease dipeptidyl peptidase I (DP I). These compounds are represented by the general formula RAB-NH-OC (O) R ', in which R is a branched or unbranched C 1-9 alkyl chain, a branched or unbranched C 2-9 alkenyl chain, a branched or unbranched C 2-9 Alkynyl chain, a C 3-9 cycloalkyl, C 4-9 cycloalkenyl, C 5-14 aryl, all of the above radicals are optionally substituted, or H is, A is an amino acid or a mimetic of this amino acid which is in peptide bond with B, B is a Amino acid or a mimetic of this amino acid, other than proline and hydroxyproline, and R 'is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl, C 2 -C 9 heterocycloalkyl, C 3 -C 9 heterocycloalkenyl, C 5-14 aryl, which can have up to 6 heteroatoms in the ring, an amino acid or a mimetic of this amino acid , all of the above radicals optionally substituted rt, or H.
Derartige Verbindungen zeichnen sich dadurch aus, daß sie in wäßrigen Lösungen, einschließlich biologischer Flüssigkeiten, chemisch stabil sind. Unmittelbar nach enzymatischer Einwirkung durch DP I auf diese Verbindungen entfalten diese ihre inhibitorische Aktivität gegenüber dem Targetenzym, was schließlich zur effizienten und vollständigen Inhibierung der DP I führt. Such connections are characterized in that they are in aqueous solutions, including biological liquids, are chemically stable. Immediately after enzymatic The influence of DP I on these connections unfold theirs inhibitory activity against the target enzyme what finally, for efficient and complete inhibition of the DP I leads.
Von Dipeptidyl Peptidase I ist bekannt, daß sie aktive, granulozytäre Serinproteasen lymphatischer Zellen aus ihren Pro- Formen freisetzt, also bei Mechanismen mitwirkt, die physiologisch durch cytotoxische Lymphozyten bei der Immunabwehr genutzt werden. Bei pathophysiologischen Entartungen zellulärer Prozesse wie malignen Transformationen myeloider und lymphatischer Zellen kann die Suppression derartiger Mechanismen zur Behandlung von Krebs- oder Immunerkrankungen oder Stoffwechselerkrankungen genutzt werden. Die erfindungsgemäßen Inhibitoren der DP I können zur Behandlung von derartigen pathophysiologischen Zuständen bzw. Erkrankungen eingesetzt werden. Dipeptidyl peptidase I is known to be active, granulocytic serine proteases of lymphatic cells from their pro Releases forms, i.e. participates in mechanisms that physiologically by cytotoxic lymphocytes in the immune system be used. With pathophysiological degeneration cellular processes like malignant transformations myeloid and Lymphatic cells can suppress such mechanisms for the treatment of cancer or immune diseases or Metabolic diseases can be used. The Inhibitors of DP I according to the invention can be used for treatment of such pathophysiological conditions or Diseases are used.
Neben Proteasen, die in unspezifische Proteolyse einbezogen sind, was letztlich den Abbau von Proteinen zu Aminosäuren bewirkt, kennt man regulatorische Proteasen, die an der Funktionalisierung (Aktivierung, Deaktivierung, Modulierung) von endogenen Peptidwirkstoffen beteiligt sind (Kirschke et al., 1995) Kräusslich & Wimmer, 1987). Insbesondere im Zusammenhang mit der Immunforschung und der Neuropeptidforschung sind eine Reihe solcher sogenannten Konvertasen, Signalpeptidasen oder Enkephalinasen entdeckt worden (Gomez et al., 1988) (Ansorge et al., 1991). In addition to proteases involved in non-specific proteolysis are what ultimately breaks down proteins into amino acids causes, one knows regulatory proteases, which on the Functionalization (activation, deactivation, modulation) of endogenous peptide agents are involved (Kirschke et al., 1995) Krausslich & Wimmer, 1987). Especially in Are related to immune research and neuropeptide research a number of such so-called convertases, signal peptidases or enkephalinases have been discovered (Gomez et al., 1988) (Ansorge et al., 1991).
Dipeptidyl Peptidase I (DP I, Peptidase Klassifizierung Clan CA, Familie C1, IUBMB Enzym Klassifizierung EC 3.4.14.1, CAS Registration Nr. 9032-68-2) wurde von Gutman & Fruton 1948 entdeckt. DP I spaltet mit relativ breiter Substratspezifität sequentiell Dipeptide von unsubstituierten N-Termini von Polypeptidsubstraten ab (McDonald et al., 1971; McDonald & Schwabe, 1977). DP I ist eine lysosomale Cysteinprotease, die durch die Abspaltung N-terminaler Dipeptide aktive Enzyme aus Proenzymen, wie Granzym A, Granzym B, Leukozyten Elastase, Cathepsin B, Neuraminidase in den lysosomalen Granula cytotoxischer T-Lymphozyten freisetzen kann (Kummer et al., 1996; Thiele & Lipsky, 1997. Dipeptidyl peptidase I (DP I, peptidase classification clan CA, family C1, IUBMB enzyme classification EC 3.4.14.1, CAS Registration No. 9032-68-2) was made by Gutman & Fruton in 1948 discovered. DP I cleaves with a relatively broad substrate specificity sequentially dipeptides of unsubstituted N-termini from Polypeptide substrates (McDonald et al., 1971; McDonald & Schwabe, 1977). DP I is a lysosomal cysteine protease that active enzymes by cleaving N-terminal dipeptides Proenzymes, such as granzyme A, granzyme B, leukocyte elastase, Cathepsin B, neuraminidase in the lysosomal granules can release cytotoxic T lymphocytes (Kummer et al., 1996; Thiele & Lipsky, 1997.
Es wird daher vermutet, daß DP I in pathologische Mechanismen wie apoptotische Prozesse, Muskeldystrophie und Krebsentstehung involviert ist (Aoyagi et al., 1983; Gelman et al., 1980; Schlangenauff et al., 1992; Shi et al., 1992). It is therefore suspected that DP I in pathological mechanisms like apoptotic processes, muscular dystrophy and Cancer formation is involved (Aoyagi et al., 1983; Gelman et al., 1980; Schlangenauff et al., 1992; Shi et al., 1992).
DP I ist als Konvertase des Blutzucker-steigernden Hormons Glukagon bekannt, das bei enzymatisch verminderter Konzentration zu lebensbedrohlicher Hypoglykämie führen kann (McDonald, J. K et al., 1971). DP I is a convertase of the blood sugar-increasing hormone Known glucagon, which is enzymatically reduced Concentration can lead to life-threatening hypoglycemia (McDonald, J.K et al., 1971).
DP I wird durch reversible und irreversible Cysteinproteaseinhibitoren wie Leupeptin bzw. E-64 nur schwach inhibiert (Nikawa et al., 1992). Stärkere reversible Inhibitoren sind Stefin A und Chicken Cystatin, Proteininhibitoren aus der Cystatin Superfamilie (Nicklin & Barrett, 1984). Eine spezifische Inhibierung wurde mit den a priori reaktiven affinity label vom Typ der Diazomethylketone und Sulphonylmethylketone erreicht (Angliker et al., 1989; Green & Shaw, 1981; Hanzlik, R. P. & Xing, R., 1998). In den letzten Jahren wurden weitere neuartige reversible DP I-Inhibitoren sowie irreversibel wirkende affinity label der DP I bekannt (Palmer et. al., 1998; Thiele et al., 1997). DP I becomes reversible and irreversible Cysteine protease inhibitors such as leupeptin or E-64 only weakly inhibited (Nikawa et al., 1992). Stronger reversible inhibitors are Stefin A and Chicken Cystatin, protein inhibitors from the Cystatin superfamily (Nicklin & Barrett, 1984). A specific inhibition was reactive with the a priori affinity label of the diazomethyl ketone and Sulphonyl methyl ketones achieved (Angliker et al., 1989; Green & Shaw, 1981; Hanzlik, R.P. & Xing, R., 1998). In recent years were other novel reversible DP I inhibitors as well known irreversible affinity label of the DP I (Palmer et. al., 1998; Thiele et al., 1997).
Im Gegensatz zu derartigen reversiblen Inhibitoren, die aufgrund von Diffusionsprozessen nur kurzzeitige Wirkungen entfalten können, und den in vitro auf das Zielenzym zwar irreversibel wirkenden affinity label, die aber durch ihren a priori vorhandenen chemisch reaktiven Rest vor ihrer Interaktion mit dem Zielprotein mit anderen Nukleophilen oder Elektrophilen in biologischen Flüssigkeiten reagieren können, zeichnen sich mechanismus-orientierte Inhibitoren dadurch aus, daß sie nur durch das Zielenzym katalytisch angegriffen und erst dadurch aktiviert werden. Derartige Inhibitoren sind auch als Selbstmord-Inaktivatoren bekannt. Solche hocheffizienten Selbstmordinaktivatoren für Cysteinproteasen wurden mit der Klasse der N-Peptidyl, O-Acyl Hydroxlamine entwickelt (Brömme et al., 1996). Inhibitoren der DP I wurden aus dieser Verbindungsklasse nicht abgeleitet, da sich DP I gegenüber typischen irreversiblen Cysteinproteaseinhibitoren wie z. B. E-64 inert verhält. In contrast to such reversible inhibitors that only short-term effects due to diffusion processes can unfold, and in vitro on the target enzyme irreversible affinity label, but by its a priori existing chemically reactive residue before their Interaction with the target protein with other nucleophiles or Electrophiles can react in biological fluids, Mechanism-oriented inhibitors are characterized by this from the fact that they are only catalytically attacked by the target enzyme and only then be activated. Such inhibitors are also known as suicide inactivators. Such highly efficient suicide inactivators for cysteine proteases have been identified developed the class of N-peptidyl, O-acyl hydroxlamine (Brömme et al., 1996). Inhibitors of DP I were derived from this Connection class not derived because DP I are opposite each other typical irreversible cysteine protease inhibitors such. B. E-64 behaves inertly.
Weiterhin neigen N-terminal ungeschützte Dipeptid-Derivate zu rapider, intramolekularer Zersetzung. Furthermore, N-terminally unprotected dipeptide derivatives tend to rapid, intramolecular decomposition.
Der Erfindung liegt daher der überraschende Befund zugrunde, daß sich erfindungsgemäße Verbindungen der allgemeinen Formel R-A-B-NH-O-C(O)R' mit einer für die Dipeptidyl Peptidase I charakteristischen Substratstruktur als hochpotente und hydrolytisch stabile irreversible Selbstmordinaktivatoren der DP I erweisen. Im Vergleich zu bisher bekannten DP I- Inhibitoren sind die erfindungsgemäßen Verbindungen außerordentlich potent. The invention is therefore based on the surprising finding that compounds of the general formula according to the invention R-A-B-NH-O-C (O) R 'with one for the dipeptidyl peptidase I characteristic substrate structure as highly potent and hydrolytically stable irreversible suicide inactivators of DP I prove. Compared to previously known DP I- The compounds according to the invention are inhibitors extremely potent.
Damit ist es möglich, selektive Inhibitoren der Dipeptidyl Peptidase I darzustellen, die sich durch hohe Stabilität und Selektivität gegenüber dem Zielenzym ausweisen. Derartige Verbindungen können zur Beeinflussung DP I-vermittelter pathologischer Prozesse dienen. Die erfindungsgemäßen Inhibitoren der DP I können in pharmazeutischen Formulierungen zur Behandlung von derartigen pathophysiologischen Zuständen bzw. Erkrankungen eingesetzt werden. This makes it possible to use selective inhibitors of dipeptidyl To represent peptidase I, which is characterized by high stability and Show selectivity towards the target enzyme. such Connections can be used to influence DP-mediated serve pathological processes. The invention Inhibitors of DP I can be used in pharmaceutical formulations Treatment of such pathophysiological conditions or Diseases are used.
Verbindungen der Formel R1-CO-NH-O-CO-R2 sind an sich bekannt, vgl. DD 294 711, wobei die Reste R1-CO- N-geschützte oder ungeschützte Aminosäurereste sowie N-geschützte oder ungeschützte Peptidylreste sein können; und die Reste R2-CO- aliphatische, verzweigte, aromatische sowie aromatische substituierte Acylreste, wie substituierte Benzoylreste, unsubstituierte heterocyclische Acylreste, primäre oder sekundäre, aliphatische, verzweigt aliphatische, heterocyclische oder aromatische, substituierte oder unsubstituierte Amine oder C-terminal geschützte oder ungeschützte Aminosäuren oder Peptide sein können. Compounds of the formula R 1 -CO-NH-O-CO-R 2 are known per se, cf. DD 294 711, where the residues R 1 can be -CO- N-protected or unprotected amino acid residues and N-protected or unprotected peptidyl residues; and the radicals R 2 -CO- aliphatic, branched, aromatic and aromatic substituted acyl radicals, such as substituted benzoyl radicals, unsubstituted heterocyclic acyl radicals, primary or secondary, aliphatic, branched aliphatic, heterocyclic or aromatic, substituted or unsubstituted amines or C-terminally protected or unprotected Amino acids or peptides can be.
Erfindungsgemäß ist nun gefunden worden, daß Verbindungen der allgemeinen Formel R-A-B-NH-O-C(O)R' überraschend gut zur Inibierung von Dipeptidyl Peptidase 1 geeignet sind, in der R eine verzweigte oder unverzweigte C1-9 Alkylkette, eine verzweigte oder unverzweigte C2-9 Alkenylkette, eine verzweigte oder unverzweigte C2-9 Alkinylkette, ein C3-9 Cycloalkyl, C4-9 Cycloalkenyl, C5-14 Aryl, alle vorstehenden Reste optional substituiert, oder H ist, A eine Aminosäure oder ein Mimetikum dieser Aminosäure ist, die in Peptidbindung mit B vorliegt, B eine Aminosäure oder ein Mimetikum dieser Aminosäure, außer Prolin und Hydroxyprolin, ist und R' eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9 Alkinylkette, ein C3-9 Cycloalkyl, C4-C9 Cycloalkenyl, C2-C9 Heterocycloalkyl, C3-C9 Heterocycloalkenyl, C5-14 Aryl, das im Ring bis zu 6 Heteroatome aufweisen kann, eine Aminosäure oder ein Mimetikum dieser Aminosäure, alle vorstehenden Reste optional substituiert, oder H ist. According to the invention, it has now been found that compounds of the general formula RAB-NH-OC (O) R 'are surprisingly well suited for inhibiting dipeptidyl peptidase 1 in which R is a branched or unbranched C 1-9 alkyl chain, a branched or unbranched C 2-9 alkenyl chain, a branched or unbranched C 2-9 alkynyl chain, a C 3-9 cycloalkyl, C 4-9 cycloalkenyl, C 5-14 aryl, all the above radicals are optionally substituted, or H, A is an amino acid or a mimetic this amino acid which is in peptide bond with B, B is an amino acid or a mimetic of this amino acid, apart from proline and hydroxyproline, and R 'is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain , a branched or unbranched C 2 -C 9 alkynyl chain, a C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl, C 2 -C 9 heterocycloalkyl, C 3 -C 9 heterocycloalkenyl, C 5-14 aryl which is in the ring up may have up to 6 heteroatoms, an amino acid or a mimetic of this amino acid, all of the above radicals are optionally substituted, or H is.
Es hat sich als besonders vorteilhaft herausgestellt, wenn der Rest R ein Phenyl- oder Naphthylrest ist, der optional einfach oder mehrfach mit C1-C6 Alkoxy, C1-C6 Alkyl, NO2-, NH2-, F-, Cl-, Br-, I- Atomen bzw. Gruppen substituiert ist. It has turned out to be particularly advantageous if the radical R is a phenyl or naphthyl radical which may optionally be mono- or polysilicon with C 1 -C 6 alkoxy, C 1 -C 6 alkyl, NO 2 -, NH 2 -, F-, Cl, Br, I atoms or groups is substituted.
Besonders bevorzugt wird, wenn R' ein Phenyl- oder
Naphthylrest ist, der optional einfach oder mehrfach mit C1-
C6 Alkoxy, C1-C6 Alkyl, NO2-, NH2-, F-, Cl-, Br-, I-Atomen
bzw. Gruppen substituiert ist, oder
wenn R' optional substituiertes
ist, wobei V gleich N oder CH und n = 1-6 ist.
It is particularly preferred if R 'is a phenyl or naphthyl radical optionally mono- or polysubstituted with C 1 - C 6 alkoxy, C 1 -C 6 alkyl, NO 2 -, NH 2 -, F-, Cl-, Br- , I atoms or groups is substituted, or
if R 'is optionally substituted
where V is N or CH and n = 1-6.
Gemäß einer weiteren Ausführungsform werden erfindungsgemäß
Verbindungen der Formel 1 bereitgestellt, wobei R' optional
substituiertes
ist, wobei T1 gleich CH oder N ist,
W1, X1, Y1, Z1 unabhängig voneinander CH2, NR1, N+(R2)2, O, S,
SO, S (R3)2, SO2 sind,
R1 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine
verzweigte oder unverzweigte C2-C9 Alkenylkette, eine
verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9
Cycloalkyl, C4-C9 Cycloalkenyl oder H ist,
R2 unabhängig voneinander eine verzweigte oder unverzweigte
C1-9 Alkylkette, eine verzweigte oder unverzweigte C2-9
Alkenylkette, eine verzweigte oder unverzweigte C2-C9
Alkinylkette, C3-9 Cycloalkyl, C4-C9 Cycloalkenyl oder H ist
und
R3 unabhängig voneinander eine verzweigte oder unverzweigte
C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9
Alkenylkette, eine verzweigte oder unverzweigte C2-C9
Alkinylkette, C3-9 Cycloalkyl, C4-C9 Cycloalkenyl oder H ist,
wobei die Verbindungen pharmazeutisch akzeptable Anionen
aufweisen können,
oder
erfindungsgemäße Verbindungen, wobei R' optional
substituiertes
ist, wobei T2 gleich C oder N+ ist,
W2, X2, Y2, Z2 unabhängig voneinander CH, N, N+R4 oder S+R5
sind,
R4 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine
verzweigte oder unverzweigte C2-C9 Alkenylkette, eine
verzweigte oder unverzweigte C2-C9 Alkinylkette, eine
Cycloalkyl, C4-C9 Cycloalkenyl oder H ist,
R5 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine
verzweigte oder unverzweigte C2-C9 Alkenylkette, eine
verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9
Cycloalkyl, C4-C9 Cycloalkenyl oder H ist, wobei die
Verbindungen pharmazeutisch akzeptable Anionen aufweisen
können, oder
oder
erfindungsgemäße Verbindungen, wobei R' optional
substituiertes
ist, wobei S, W3, X3, Y3, Z3 unabhängig voneinander CH, N+R7
oder S+R8 sind,
R7 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine
verzweigte oder unverzweigte C2-C9 Alkenylkette, eine
verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9
Cycloalkyl, C4-C9 Cycloalkenyl oder H ist,
R8 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine
verzweigte oder unverzweigte C2-C9 Alkenylkette, eine
verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9
Cycloalkyl, C4-C9 Cycloalkenyl oder H ist, wobei die
Verbindungen pharmazeutisch akzeptable Anionen aufweisen
können,
oder
erfindungsgemäße Verbindungen, wobei R' optional
substituiertes
ist, wobei T3 gleich C oder N+ ist, wobei die Verbindungen
pharmazeutisch akzeptable Anionen aufweisen können.
According to a further embodiment, compounds of formula 1 are provided according to the invention, where R 'is optionally substituted
where T 1 is CH or N,
W 1 , X 1 , Y 1 , Z 1 are independently CH 2 , NR 1 , N + (R 2 ) 2 , O, S, SO, S (R 3 ) 2 , SO 2 ,
R 1 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. .
R 2 is independently a branched or unbranched C 1-9 alkyl chain, a branched or unbranched C 2-9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. and
R 3 independently of one another is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or Is H, where the compounds may have pharmaceutically acceptable anions,
or
Compounds according to the invention, where R 'is optionally substituted
where T 2 is C or N + ,
W 2 , X 2 , Y 2 , Z 2 are independently CH, N, N + R 4 or S + R 5 ,
R 4 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a cycloalkyl, C 4 -C 9 cycloalkenyl or H,
R 5 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. , wherein the compounds can have pharmaceutically acceptable anions, or
or
Compounds according to the invention, where R 'is optionally substituted
where S, W 3 , X 3 , Y 3 , Z 3 are independently CH, N + R 7 or S + R 8 ,
R 7 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. .
R 8 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. , where the compounds can have pharmaceutically acceptable anions,
or
Compounds according to the invention, where R 'is optionally substituted
where T 3 is C or N + , where the compounds may have pharmaceutically acceptable anions.
Die in der Beschreibung und den Ansprüchen definierten Reste R' können einfach oder mehrfach mit C1-C6 Alkoxy, C1-C6 Alkyl, NO2-, NH2-, F-, Cl-, Br-, I- Atomen bzw. Gruppen substituiert sein, wobei eine einfache oder zweifache Substitution bevorzugt ist. The radicals R 'defined in the description and the claims can be mono- or polysubstituted by C 1 -C 6 alkoxy, C 1 -C 6 alkyl, NO 2 , NH 2 , F, Cl, Br, I atoms or groups may be substituted, with a single or double substitution being preferred.
Weiter werden erfindungsgemäß Verbindungen offenbart, bei denen R' eine Aminosäure oder Mimetikum dieser Aminosäure ist. According to the invention, compounds are also disclosed in which R 'is an amino acid or mimetic of this amino acid is.
Die erfindungsgemäßen Verbindungen können auch als Prodrugs vorliegen. The compounds according to the invention can also be used as prodrugs available.
Erfindungsgemäß werden weiter pharmazeutische Zusammensetzungen bereitgestellt, die mindestens eine erfindungsgemäße Verbindung, optional in Kombination mit an sich üblichen Trägern und/oder Adjuvantien etc., umfassen. According to the invention further pharmaceutical Compositions provided that at least one of the invention Connection, optionally in combination with conventional ones Carriers and / or adjuvants etc. include.
Die erfindungsgemäßen Verbindungen bzw. Zusammensetzungen können zur in vivo Inhibierung des Enzyms Dipeptidyl Peptidase I oder zur DP I ähnlichen Enzymen verwendet werden. The compounds or compositions according to the invention can inhibit the enzyme dipeptidyl in vivo Peptidase I or enzymes similar to DP I can be used.
Insbesondere können sie zur Behandlung von Erkrankungen von Säugern verwendet werden, die durch Modulation der DP I-Aktivität in verschiedenen Zellen, Geweben und Organen beeinflußt werden können. In particular, they can be used to treat diseases of Mammals used by modulating the DP I activity in different cells, tissues and organs affected can be.
Sie sind insbesondere zur Behandlung von DP I-vermittelten malignen Zell-Entartungen, Immun- und Stoffwechselerkrankungen des Menschen geeignet. They are especially I-mediated for the treatment of DP malignant cell degeneracy, immune and Metabolic diseases of humans suitable.
Ferner betrifft die vorliegende Erfindung die Verwendung der erfindungsgemäßen Verbindungen und Zusammensetzungen zur Verbesserung des Wundheilungsprozesses und zur Therapie von beeinträchtigter Wundheilung des Menschen. Furthermore, the present invention relates to the use of the Compounds and compositions according to the invention for Improvement of the wound healing process and for the therapy of impaired wound healing in humans.
Insbesondere können die Verbindungen in Prodrugform vorliegen
und zum Einsatz kommen.
Literaturverzeichnis
Ansorge, S., Schön, E., and Kunz, D. (1991). Membrane-bound
peptidases of lymphocytes: functional implications.
Biomed. Biochim. Acta 50, 799-807.
Angliker, H., Wikstrom, P., Kirschke, H., and Shaw, E.
(1989). The inactivation of the cysteinyl
exopeptidases cathepsin H and C by affinity - labelling
reagents. Biochem. J. 262, 63-68.
Aoyagi T., Wada, T., Kojima, F., Nagai, M., Miyoshino, S.,
and Umezawa, H. (1983). Two different modes of
enzymatic changes in serum with progression of
Duchenne muscular dystrophy. Clin. Chim. Acta 129,
165-173.
Brömme, D., Neumann, U., Kirschke, H., and Demuth, H.-U.
(1996). Novel N-peptidyl-O-acyl hydroxamates:
selective inhibitors of cysteine proteinases.
Biochim. Biophys. Acta. 1202, 271-276.
Gelman B. B., Papa, L., Davis, M. H., and Gruenstein, E.
(1980). Decreased lysosomal dipeptidyl
aminopeptidase I activity in cultured human skin
fibroblasts in Duchenne's muscular dystrophy. J.
Clin. Invest. 65, 1398-1406.
Gomez, S., Gluschankof, P., Lepage, A., and Cohen, P. (1988).
Relationship between endo- and exopeptidases in a
processing enzyme system: activation of an
endoprotease by the aminopeptidase B-like activity in
somatostatin-28 convertase. Proc Natl Acad Sci USA
85, 5468-5472.
Green G. D. J. & Shaw, E. (1981). Peptidyl diazomethyl ketones
are specific inactivators of thiol proteinases. J.
Biol. Chem. 256, 1923-1928.
Gutman H. R. & Fruton, J. S. (1948). On the proteolytic enzymes
of animal tissues VIII. An intracellular enzyme
related to chymotrypsin. J. Biol. Chem. 174, 851-858.
Hanzlik, R. P. & Xing, R. (1998). Azapeptides as inhibitors
and active site titrants for cysteine Proteinases.
J. Med. Chem. 41, 1344-1351.
Kirschke, H., Barrett, A. J., and Rawlings, N. D. (1995).
Proteinases 1: lysosomal cysteine proteinases.
Protein Profile 2, 1581-1643.
Kräusslich, H.-G. and Wimmer, E. (1987). Viral Proteinases.
Ann. Rev. Biochem. 57, 701
Kummer, J. A., Kamp, A. M., Citarella, F., Horrevoets, A. J. G.,
and Hack, C. E. (1996). Expression of human
recombinant granzyme A zymogen and its activation by the
cysteine proteinase cathepsin C. J. Biol. Chem.
271, 9281-9286.
McDonald, J. K, Callahan, P. X., Ellis, S., and Smith, R. E.
(1971). Polypeptide degradation by dipeptidyl
aminopeptidase I (cathepsin C) and related peptidases.
In: Tissue Proteinases (Barrett, A. J. & Dingle,
J. T., eds). Amsterdam: North-Holland Publishing,
pp. 69-107.
McDonald, J. K. & Schwabe, C. (1977). Intracellular
exopeptidases. In: Proteinases in Mammalian Cells and
Tissues (Barrett, A. J., ed.). Amsterdam: North Holland
Publishing, pp. 311-391.
Nicklin, M. J. H. & Barrett, A. J. (1984). Inhibition of
cysteine proteinases and dipeptidyl peptidase I by
eggwhite cystatin. Biochem. J. 223, 245-253.
Nikawa, T., Towatari, T., and Katunuma, N. (1992).
Purification and characterization of cathepsin J from rat
liver. Eur. J. Biochem. 204, 381-393.
Palmer, J. T., Rasnick, D., and Klaus, J. L. (1998).
Reversible protease inhibitors. US-Pat. 5,776,718.
Schlagenauff, B., Klessen, C., Teichmann-Dörr, S.,
Breuninger, H., and Rassner, G. (1992). Demonstration of
proteases in basal cell carcinomas. A histochemical
study using amino acid-4-methoxy-2-naphthylamides
as chromogenic substrates. Cancer 70, 1133-1140.
Shi, L., Kam, C.-M., Powers, J. C., Aebersold, R., and
Greenberg, A. H. (1992). Purification of three cytotoxic
lymphocyte granule serine proteases that induce
apoptosis through distinct substrate and target
cell interactions. J. Exp. Med. 176, 1521-1529.
Thiele, D. L., Lipsky, P. E., and McGuire, M. J. (1997).
Dipeptidyl Peptidase-I inhibitors and uses thereof. US-Pat. 5,602,102.
In particular, the compounds can be in prodrug form and can be used. Bibliography Ansorge, S., Schön, E., and Kunz, D. (1991). Membrane-bound peptidases of lymphocytes: functional implications. Biomed. Biochim. Acta 50, 799-807.
Angliker, H., Wikstrom, P., Kirschke, H., and Shaw, E. (1989). The inactivation of the cysteinyl exopeptidases cathepsin H and C by affinity - labeling reagents. Biochem. J. 262, 63-68.
Aoyagi T., Wada, T., Kojima, F., Nagai, M., Miyoshino, S., and Umezawa, H. (1983). Two different modes of enzymatic changes in serum with progression of Duchenne muscular dystrophy. Clin. Chim. Acta 129, 165-173.
Brömme, D., Neumann, U., Kirschke, H., and Demuth, H.-U. (1996). Novel N-peptidyl-O-acyl hydroxamates: selective inhibitors of cysteine proteinases. Biochim. Biophys. Acta. 1202, 271-276.
Gelman BB, Papa, L., Davis, MH, and Gruenstein, E. (1980). Decreased lysosomal dipeptidyl aminopeptidase I activity in cultured human skin fibroblasts in Duchenne's muscular dystrophy. J. Clin. Invest. 65, 1398-1406.
Gomez, S., Gluschankof, P., Lepage, A., and Cohen, P. (1988). Relationship between endo- and exopeptidases in a processing enzyme system: activation of an endoprotease by the aminopeptidase B-like activity in somatostatin-28 convertase. Proc Natl Acad Sci USA 85, 5468-5472.
Green GDJ & Shaw, E. (1981). Peptidyl diazomethyl ketones are specific inactivators of thiol proteinases. J. Biol. Chem. 256, 1923-1928.
Gutman HR & Fruton, JS (1948). On the proteolytic enzymes of animal tissues VIII. An intracellular enzyme related to chymotrypsin. J. Biol. Chem. 174, 851-858.
Hanzlik, RP & Xing, R. (1998). Azapeptides as inhibitors and active site titrants for cysteine proteinases. J. Med. Chem. 41, 1344-1351.
Kirschke, H., Barrett, AJ, and Rawlings, ND (1995). Proteinases 1: lysosomal cysteine proteinases. Protein Profile 2, 1581-1643.
Krausslich, H.-G. and Wimmer, E. (1987). Viral proteinases. Ann. Rev. Biochem. 57, 701
Kummer, JA, Kamp, AM, Citarella, F., Horrevoets, AJG, and Hack, CE (1996). Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin CJ Biol. Chem. 271, 9281-9286.
McDonald, J.K. Callahan, PX, Ellis, S., and Smith, RE (1971). Polypeptide degradation by dipeptidyl aminopeptidase I (cathepsin C) and related peptidases. In: Tissue Proteinases (Barrett, AJ & Dingle, JT, eds). Amsterdam: North-Holland Publishing, pp. 69-107.
McDonald, JK & Schwabe, C. (1977). Intracellular exopeptidases. In: Proteinases in Mammalian Cells and Tissues (Barrett, AJ, ed.). Amsterdam: North Holland Publishing, pp. 311-391.
Nicklin, MJH & Barrett, AJ (1984). Inhibition of cysteine proteinases and dipeptidyl peptidase I by eggwhite cystatin. Biochem. J. 223, 245-253.
Nikawa, T., Towatari, T., and Katunuma, N. (1992). Purification and characterization of cathepsin J from rat liver. Eur. J. Biochem. 204, 381-393.
Palmer, JT, Rasnick, D., and Klaus, JL (1998). Reversible protease inhibitors. US Pat. 5,776,718.
Schlagenauff, B., Klessen, C., Teichmann-Dörr, S., Breuninger, H., and Rassner, G. (1992). Demonstration of proteases in basal cell carcinomas. A histochemical study using amino acid-4-methoxy-2-naphthylamides as chromogenic substrates. Cancer 70, 1133-1140.
Shi, L., Kam, C.-M., Powers, JC, Aebersold, R., and Greenberg, AH (1992). Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J. Exp. Med. 176, 1521-1529.
Thiele, DL, Lipsky, PE, and McGuire, MJ (1997). Dipeptidyl peptidase-I inhibitors and uses thereof. US Pat. 5,602,102.
Claims (17)
in der R eine verzweigte oder unverzweigte C1-9 Alkylkette, eine verzweigte oder unverzweigte C2-9 Alkenylkette, eine verzweigte oder unverzweigte C2-9 Alkinylkette, ein C3-9 Cycloalkyl, C4-9 Cycloalkenyl, C5-14 Aryl, alle vorstehenden Reste optional substituiert, oder H ist, A eine Aminosäure oder ein Mimetikum dieser Aminosäure ist, die in Peptidbindung mit B vorliegt, B eine Aminosäure oder ein Mimetikum dieser Aminosäure, außer Prolin und Hydroxyprolin, ist und R' eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9 Alkinylkette, ein C3-9 Cycloalkyl, C4-C9 Cycloalkenyl, C2-C9 Heterocycloalkyl, C3-C9 Heterocycloalkenyl, C5-14 Aryl, das im Ring bis zu 6 Heteroatome aufweisen kann, eine Aminosäure oder ein Mimetikum dieser Aminosäure, alle vorstehenden Reste optional substituiert, oder H ist. 1. Compounds of the general formula 1 and the pharmaceutical salts thereof,
in which R is a branched or unbranched C 1-9 alkyl chain, a branched or unbranched C 2-9 alkenyl chain, a branched or unbranched C 2-9 alkynyl chain, a C 3-9 cycloalkyl, C 4-9 cycloalkenyl, C 5-14 Aryl, all of the above radicals are optionally substituted, or H is, A is an amino acid or a mimetic of this amino acid which is in peptide bond with B, B is an amino acid or a mimetic of this amino acid, except proline and hydroxyproline, and R 'is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl, C 2 -C 9 heterocycloalkyl , C 3 -C 9 heterocycloalkenyl, C 5-14 aryl which can have up to 6 heteroatoms in the ring, an amino acid or a mimetic of this amino acid, all of the above radicals are optionally substituted, or H
ist, wobei V gleich N oder CH und n = 1-6 ist. 4. Compounds according to claim 1 or 2, wherein R 'optionally substituted
where V is N or CH and n = 1-6.
ist, wobei T1 gleich CH oder N ist,
W1, X1, Y1, Z1 unabhängig voneinander CH2, NR1, N+(R2)2, O, S, SO, S(R3)2, SO2 sind,
R1 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9 Cycloalkyl, C4-C9 Cycloalkenyl oder H ist,
R2 unabhängig voneinander eine verzweigte oder unverzweigte C1-9 Alkylkette, eine verzweigte oder unverzweigte C2-9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9Alkinylkette, C3-9 Cycloalkyl, C4-C9 Cycloalkenyl oder H ist und
R3 unabhängig voneinander eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9 Cycloalkyl, C4-C9 Cycloalkenyl oder H ist,
wobei die Verbindungen pharmazeutisch akzeptable Anionen aufweisen können. 5. Compounds according to claim 1 or 2, wherein R 'optionally substituted
where T 1 is CH or N,
W 1 , X 1 , Y 1 , Z 1 are independently CH 2 , NR 1 , N + (R 2 ) 2 , O, S, SO, S (R 3 ) 2 , SO 2 ,
R 1 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. .
R 2 is independently a branched or unbranched C 1-9 alkyl chain, a branched or unbranched C 2-9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. and
R 3 independently of one another is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H is
the compounds may have pharmaceutically acceptable anions.
ist, wobei T2 gleich C oder N+ ist,
W2, X2, Y2, Z2 unabhängig voneinander CH, N, N+R4 oder S+R5 sind,
R4 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9 Cycloalkyl, C4-C9 Cycloalkenyl oder H ist,
R5 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9 Cycloalkyl, C4-C9 Cycloalkenyl oder H ist, wobei die Verbindungen pharmazeutisch akzeptable Anionen aufweisen können. 6. Compounds according to claim 1 or 2, wherein R 'optionally substituted
where T 2 is C or N + ,
W 2 , X 2 , Y 2 , Z 2 are independently CH, N, N + R 4 or S + R 5 ,
R 4 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. .
R 5 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. , wherein the compounds may have pharmaceutically acceptable anions.
ist, wobei S, W3, X3, Y3, Z3 unabhängig voneinander CH, N+R7 oder S+R8 sind,
R7 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9 Cycloalkyl, C4-C9 Cycloalkenyl oder H ist,
R8 eine verzweigte oder unverzweigte C1-C9 Alkylkette, eine verzweigte oder unverzweigte C2-C9 Alkenylkette, eine verzweigte oder unverzweigte C2-C9 Alkinylkette, C3-9 Cycloalkyl, C4-C9 Cycloalkenyl oder H ist, wobei die Verbindungen pharmazeutisch akzeptable Anionen aufweisen können. 7. Compounds according to claim 1 or 2, wherein R 'optionally substituted
where S, W 3 , X 3 , Y 3 , Z 3 are independently CH, N + R 7 or S + R 8 ,
R 7 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. .
R 8 is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3-9 cycloalkyl, C 4 -C 9 cycloalkenyl or H. , wherein the compounds may have pharmaceutically acceptable anions.
ist, wobei T3 gleich C oder N+ ist, wobei die Verbindungen pharmazeutisch akzeptable Anionen aufweisen können. 8. Compounds according to claim 1 or 2, wherein R 'optionally substituted
where T 3 is C or N + , where the compounds may have pharmaceutically acceptable anions.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10143840A DE10143840A1 (en) | 2001-09-06 | 2001-09-06 | New acylated hydroxamates useful for the treatment of e.g. wound healing |
PCT/EP2002/010020 WO2003022871A2 (en) | 2001-09-06 | 2002-09-06 | Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i |
EP02779316A EP1423410A2 (en) | 2001-09-06 | 2002-09-06 | Peptides having a c-terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i |
JP2003526944A JP2005511505A (en) | 2001-09-06 | 2002-09-06 | Novel inhibitors of dipeptidyl peptidase I |
AU2002342657A AU2002342657A1 (en) | 2001-09-06 | 2002-09-06 | Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i |
US10/236,136 US6844316B2 (en) | 2001-09-06 | 2002-09-06 | Inhibitors of dipeptidyl peptidase I |
US10/997,821 US7144856B2 (en) | 2001-09-06 | 2004-11-24 | Inhibitors of dipeptidyl peptidase I |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10143840A DE10143840A1 (en) | 2001-09-06 | 2001-09-06 | New acylated hydroxamates useful for the treatment of e.g. wound healing |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10143840A1 true DE10143840A1 (en) | 2003-03-27 |
Family
ID=7698010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10143840A Withdrawn DE10143840A1 (en) | 2001-09-06 | 2001-09-06 | New acylated hydroxamates useful for the treatment of e.g. wound healing |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1423410A2 (en) |
JP (1) | JP2005511505A (en) |
AU (1) | AU2002342657A1 (en) |
DE (1) | DE10143840A1 (en) |
WO (1) | WO2003022871A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2017620A3 (en) * | 2004-04-28 | 2009-04-22 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1) |
EP2116235A1 (en) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US7816364B2 (en) | 2006-04-11 | 2010-10-19 | Arena Pharmaceuticals, Inc. | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto |
US7833730B2 (en) | 2006-04-11 | 2010-11-16 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
US7838254B2 (en) | 2008-04-07 | 2010-11-23 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1608317B1 (en) | 2003-03-25 | 2012-09-26 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
ATE399763T1 (en) * | 2003-05-30 | 2008-07-15 | Prozymex As | PROTEASE INHIBITORS |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7470700B2 (en) | 2003-08-13 | 2008-12-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007505121A (en) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | Dipeptidyl peptidase inhibitor |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AU2004318013B8 (en) | 2004-03-15 | 2011-10-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2008501714A (en) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | Dipeptidyl peptidase inhibitor |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
JP2008524331A (en) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | Dipeptidyl peptidase inhibitor |
CA2622472C (en) | 2005-09-14 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
CN101360723A (en) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | Process for the preparation of pyrimidinedione derivatives |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
CN113292465B (en) * | 2021-06-17 | 2022-11-08 | 贵州医科大学 | Cysteine derivative and synthesis method and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR016751A1 (en) * | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD |
DE19834610A1 (en) * | 1998-07-31 | 2000-02-24 | Probiodrug Ges Fuer Arzneim | New N-dipeptidyl O-acyl hydroxylamine derivatives useful as dipeptidyl peptidase I inhibitors, e.g. for treating cancer or immunological or metabolic disorders |
-
2001
- 2001-09-06 DE DE10143840A patent/DE10143840A1/en not_active Withdrawn
-
2002
- 2002-09-06 AU AU2002342657A patent/AU2002342657A1/en not_active Abandoned
- 2002-09-06 EP EP02779316A patent/EP1423410A2/en not_active Withdrawn
- 2002-09-06 JP JP2003526944A patent/JP2005511505A/en active Pending
- 2002-09-06 WO PCT/EP2002/010020 patent/WO2003022871A2/en active Application Filing
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2017620A3 (en) * | 2004-04-28 | 2009-04-22 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1) |
EP2116235A1 (en) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US7803754B2 (en) | 2005-01-10 | 2010-09-28 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US7803753B2 (en) | 2005-01-10 | 2010-09-28 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US8198232B2 (en) | 2005-01-10 | 2012-06-12 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US8030270B2 (en) | 2005-01-10 | 2011-10-04 | Arena Pharmaceuticals, Inc. | Methods for identifying GLP-1 secretagogues |
US8022034B2 (en) | 2005-01-10 | 2011-09-20 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US8003597B2 (en) | 2005-01-10 | 2011-08-23 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US7816364B2 (en) | 2006-04-11 | 2010-10-19 | Arena Pharmaceuticals, Inc. | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto |
EP2253311A2 (en) | 2006-04-11 | 2010-11-24 | Arena Pharmaceuticals, Inc. | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto |
US8017574B2 (en) | 2006-04-11 | 2011-09-13 | Arena Pharmaceuticals, Inc. | Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretagogues |
US8026074B2 (en) | 2006-04-11 | 2011-09-27 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
US8026212B2 (en) | 2006-04-11 | 2011-09-27 | Arena Pharmaceuticals, Inc. | Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues |
US7833730B2 (en) | 2006-04-11 | 2010-11-16 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
US8101626B2 (en) | 2006-04-11 | 2012-01-24 | Arena Pharmaceuticals, Inc. | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto |
US8580526B2 (en) | 2006-04-11 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion |
US7838254B2 (en) | 2008-04-07 | 2010-11-23 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
US8883714B2 (en) | 2008-04-07 | 2014-11-11 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues |
US8486646B2 (en) | 2008-04-07 | 2013-07-16 | Arena Pharmaceuticals, Inc. | Methods of using a G protein-coupled receptor to identify peptide YY (PYY) secretagogues |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10772865B2 (en) | 2015-03-09 | 2020-09-15 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11400072B2 (en) | 2015-03-09 | 2022-08-02 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Also Published As
Publication number | Publication date |
---|---|
WO2003022871A2 (en) | 2003-03-20 |
WO2003022871A3 (en) | 2003-11-13 |
AU2002342657A1 (en) | 2003-03-24 |
JP2005511505A (en) | 2005-04-28 |
EP1423410A2 (en) | 2004-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10143840A1 (en) | New acylated hydroxamates useful for the treatment of e.g. wound healing | |
US5444042A (en) | Method of treatment of neurodegeneration with calpain inhibitors | |
US7608577B2 (en) | Peptidyl ketones as inhibitors of DPIV | |
RU2305553C2 (en) | New dipeptidyl peptidase iv inhibitors and uses thereof as hypotensive agent | |
DE69528888T3 (en) | Regulation of NF-κB activity by proteasomes | |
US6844316B2 (en) | Inhibitors of dipeptidyl peptidase I | |
CA2138124A1 (en) | Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity | |
RU2299066C2 (en) | Novel inhibitors of dipeptidyl peptidase iv and their using as anticancer agents | |
JPH06504061A (en) | Use of calpain inhibitors in the treatment and prevention of neurodegeneration | |
JP2005511505A6 (en) | Novel inhibitors of dipeptidyl peptidase I | |
US20050014946A1 (en) | Substituted amino ketone compounds | |
DE69726426T2 (en) | SUPPRESSION OF IMMUNE RESPONSE BY INHIBITING CATHEPSIN S | |
JP2004521149A (en) | Novel dipeptidyl peptidase IV inhibitors and their use as anticancer agents | |
US7521427B2 (en) | Peptidyl allyl sulfones | |
AU2002331224A1 (en) | Peptidyl ketones as inhibitors of DPIV | |
JP2005518350A (en) | Substituted amino ketone compounds | |
DE69434070T2 (en) | KININOGEN INHIBITORS | |
JPH07503715A (en) | trypsin inhibitor | |
US20040048327A1 (en) | Aza-peptide epoxides | |
EP1188765B1 (en) | Medical Use of Mechanism-oriented inhibitors of dipeptidyl peptidase I | |
Nakajima et al. | Y-29794—a non-peptide prolyl endopeptidase inhibitor that can penetrate into the brain | |
JP3403794B2 (en) | Antihypertensive and hypotensive functional food | |
Xu | Synthesis of Novel Sulfonamide-Based Calpain Inhibitors and Their Potential as Anti-Tumor Agents | |
AU2378299A (en) | Use of calpain inhibitors in the inhibition and treatment of neurodegeneration | |
JPH06256209A (en) | Preventive and therapeutic agent against ulcer of eye ball and its peripheral tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8130 | Withdrawal |